# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001764013-26-000093
Filing Date
2026-07-22
Accepted
2026-07-22 16:13:20
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | defa14aadditionalmaterials.htm | DEFA14A | 13591
2 |  | immunovantinc_vxnoticeanda.jpg | GRAPHIC | 492465
3 |  | immunovantinc_vxnoticeandaa.jpg | GRAPHIC | 384072
| Complete submission text file | 0001764013-26-000093.txt |  | 1221517

Mailing Address 1000 PARK FORTY PLAZA DURHAM NC 27713
Business Address 1000 PARK FORTY PLAZA DURHAM NC 27713 917-410-3120
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-38906 | Film No.: 261193829
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)